Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 9/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18643503 | 1.00 | FFAR4 (0.47) | FFAR4RAPGEF4NPSR1MEN1KMT2A | |
| SCHEMBL12269615 | 0.84 | NPSR1 (0.44) | FFAR4RAPGEF4NPSR1SMN1; SMN2LMNA | |
| SCHEMBL3297150 | 0.78 | NPSR1 (0.41) | FFAR4RAPGEF4NPSR1MEN1KMT2A | |
| SCHEMBL28131012 | 0.76 | NPSR1 (0.39) | FFAR4RAPGEF4NPSR1MEN1KMT2A | |
| SCHEMBL13936547 | 0.73 | SLC6A2 (0.45) | FFAR4KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1305440 | 0.73 | SMN1; SMN2 (0.40) | FFAR4MEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL7193963 | 0.73 | SMN1; SMN2 (0.40) | FFAR4MEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL23005030 | 0.71 | HTT (0.63) | SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL14587753 | 0.70 | RAPGEF4 (0.55) | FFAR4RAPGEF4 | |
| SCHEMBL19367695 | 0.70 | RAPGEF4 (0.55) | FFAR4RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | FFAR4 2976/4885RAPGEF4 1274/4885NPSR1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.